Business
Notice of HY Results and Investor Presentation
Notice of HY Results and Investor Presentation.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\nSareum Holdings PLC \n(\"Sareum\" or the \"Company\")\nNotice of Half-Year Results and Investor Presentation\n \nCambridge, UK, 20 March 2025 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited half-year results for the six months ended 31 December 2024 on Tuesday, 25 March 2025.\nOn the same day at 14:00 GMT, the Company will be holding a live presentation to investors via the Investor Meet Company platform.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted before the event via the Investor Meet Company dashboard up until 25 March 2025, 09:00 GMT, or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor\nInvestors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.\nA copy of the presentation will be made available on the Company's website following the presentation.\n- ENDS-\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\nStephen Parker, Executive Chairman\n\n\n \n01223 497700\[email protected]\n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Dance / James Bellman\n \n\n\n \n020 7409 3494\n\n\n\n\nOberon Capital (Joint Broker)\nMike Seabrook / Nick Lovering\n \n\n\n \n020 3179 5300\n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Noyce\n \n\n\n \n020 3764 2341\n\n\n\n\nICR Healthcare (Financial PR)\nJessica Hodgson / Davide Salvi\n\n\n \n020 3709 5700\n\n\n\n\n \nAbout Sareum\nSareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.\nThe Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, and is planned to enter clinical development with an initial focus on psoriasis.\nSareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer i...